AEON Biopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AEON research report →
About the company
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis.
- CEO
- Robert Bancroft
- IPO
- 2023
- Employees
- 5
- HQ
- Newport Beach, CA, US
Price Chart
- Market Cap
- $8.45M
- P/E
- -0.14
- P/S
- 0.00
- P/B
- -0.52
- EV/EBITDA
- -0.20
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 223.66%
- ROIC
- -823.75%
- Revenue
- $0 · 0.00%
- Net Income
- $-39,222,000 · -193.37%
- EPS
- $-3.95 · -105.08%
- Op Income
- $-12,803,000
- FCF YoY
- 14.69%
- 52W High
- $1.45
- 52W Low
- $0.51
- 50D MA
- $0.81
- 200D MA
- $0.95
- Beta
- 0.61
- Avg Volume
- 78.02K
Get TickerSpark's AI analysis on AEON
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 17, 26 | Thunen Shelley B | other | 222,684 |
| Jun 17, 26 | PALMISANO ROBERT J | other | 222,684 |
| Jun 17, 26 | Forth Marc | other | 222,684 |
| Jun 17, 26 | FISCHER JOST | other | 222,684 |
| Jun 17, 26 | Carter Eric G | other | 222,684 |
| Apr 2, 26 | Bencich John | other | 754,717 |
| Apr 1, 26 | Bencich John | other | 0 |
| Mar 4, 26 | Oh Chad | other | 1,316,872 |
| Feb 17, 26 | Oh Chad | other | 862,500 |
| Mar 4, 26 | Wilson Alexander Blair | other | 1,316,872 |
Our AEON coverage
Recent articles, reports, and earnings notes.
No research on AEON yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AEON report →Similar companies
Peers in the same neighborhood.